# Cerence Inc.: financial statements, quarterly

CRNC · Nasdaq · CIK 1768267 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/crnc.md) · [Financials](/companies/crnc/financials.md) · [Filings](/companies/crnc/filings.md) · [Insiders](/companies/crnc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crnc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [80.8 d](/filings/0001628280-25-053372.md) | [138](/filings/0000950170-25-015440.md) | [67.8](/filings/0000950170-25-065890.md) | [70.5](/filings/0001628280-25-038378.md) | [54.8 d](/filings/0001628280-25-053372.md) | [50.9](/filings/0001628280-26-005569.md) | [78.0](/filings/0001628280-26-032139.md) | [62.2](/filings/0001628280-26-054339.md) | [60.6 d](/filings/0001628280-25-053372.md) | [115](/filings/0001628280-26-005569.md) | [64.2](/filings/0001628280-26-032139.md) | [69.6](/filings/0001628280-26-054339.md) |
| Cost of revenue | $m | [23.0 d](/filings/0001628280-25-053372.md) | [26.3](/filings/0000950170-25-015440.md) | [20.9](/filings/0000950170-25-065890.md) | [20.1](/filings/0001628280-25-038378.md) | [19.9 d](/filings/0001628280-25-053372.md) | [17.8](/filings/0001628280-26-005569.md) | [17.8](/filings/0001628280-26-032139.md) | [16.3](/filings/0001628280-26-054339.md) | [16.6 d](/filings/0001628280-25-053372.md) | [15.7](/filings/0001628280-26-005569.md) | [16.9](/filings/0001628280-26-032139.md) | [16.7](/filings/0001628280-26-054339.md) |
| Gross profit | $m | [57.7 d](/filings/0001628280-25-053372.md) | [112](/filings/0000950170-25-015440.md) | [46.9](/filings/0000950170-25-065890.md) | [50.4](/filings/0001628280-25-038378.md) | [34.9 d](/filings/0001628280-25-053372.md) | [33.1](/filings/0001628280-26-005569.md) | [60.2](/filings/0001628280-26-032139.md) | [45.9](/filings/0001628280-26-054339.md) | [44.0 d](/filings/0001628280-25-053372.md) | [99.4](/filings/0001628280-26-005569.md) | [47.3](/filings/0001628280-26-032139.md) | [52.9](/filings/0001628280-26-054339.md) |
| Research and development | $m | [35.1 d](/filings/0001628280-25-053372.md) | [33.3](/filings/0000950170-25-015440.md) | [31.8](/filings/0000950170-25-065890.md) | [31.2](/filings/0001628280-25-038378.md) | [25.2 d](/filings/0001628280-25-053372.md) | [20.9](/filings/0001628280-26-005569.md) | [23.3](/filings/0001628280-26-032139.md) | [27.2](/filings/0001628280-26-054339.md) | [26.4 d](/filings/0001628280-25-053372.md) | [24.7](/filings/0001628280-26-005569.md) | [30.3](/filings/0001628280-26-032139.md) | [29.2](/filings/0001628280-26-054339.md) |
| Operating income | $m | [3.9 d](/filings/0001628280-25-053372.md) | [58.6](/filings/0000950170-25-015440.md) | [(264)](/filings/0000950170-25-065890.md) | [(355)](/filings/0001628280-25-038378.md) | [(19.2) d](/filings/0001628280-25-053372.md) | [(16.9)](/filings/0001628280-26-005569.md) | [17.4](/filings/0001628280-26-032139.md) | [(0.9)](/filings/0001628280-26-054339.md) | [(1.8) d](/filings/0001628280-25-053372.md) | [29.3](/filings/0001628280-26-005569.md) | [(2.4)](/filings/0001628280-26-032139.md) | [1.9](/filings/0001628280-26-054339.md) |
| Interest expense | $m | [3.1 d](/filings/0000950170-24-130642.md) | [3.2](/filings/0000950170-25-015440.md) | [3.1](/filings/0000950170-25-065890.md) | [3.1](/filings/0000950170-24-094836.md) | [3.1 d](/filings/0000950170-24-130642.md) | [3.4](/filings/0000950170-25-015440.md) | [2.7](/filings/0000950170-25-065890.md) | [2.4](/filings/0001628280-26-054339.md) | [1.7 d](/filings/0001628280-25-053372.md) | [1.7](/filings/0001628280-26-005569.md) | [1.5](/filings/0001628280-26-032139.md) | [1.5](/filings/0001628280-26-054339.md) |
| Income tax | $m | [11.9 d](/filings/0001628280-25-053372.md) | [34.3](/filings/0000950170-25-015440.md) | [11.6](/filings/0000950170-25-065890.md) | [(42.6)](/filings/0001628280-25-038378.md) | [0.0 d](/filings/0001628280-25-053372.md) | [5.7](/filings/0001628280-26-005569.md) | [(5.6)](/filings/0001628280-26-032139.md) | [1.9](/filings/0001628280-26-054339.md) | [7.9 d](/filings/0001628280-25-053372.md) | [35.3](/filings/0001628280-26-005569.md) | [(4.7)](/filings/0001628280-26-032139.md) | [0.0](/filings/0001628280-26-054339.md) |
| Net income | $m | [(11.6) d](/filings/0001628280-25-053372.md) | [23.9](/filings/0000950170-25-015440.md) | [(278)](/filings/0000950170-25-065890.md) | [(314)](/filings/0001628280-25-038378.md) | [(20.4) d](/filings/0001628280-25-053372.md) | [(24.3)](/filings/0001628280-26-005569.md) | [21.7](/filings/0001628280-26-032139.md) | [(2.7)](/filings/0001628280-26-054339.md) | [(13.4) d](/filings/0001628280-25-053372.md) | [(5.2)](/filings/0001628280-26-005569.md) | [1.7](/filings/0001628280-26-032139.md) | [1.5](/filings/0001628280-26-054339.md) |
| Diluted EPS | $ per share | not reported | [0.53](/filings/0000950170-25-015440.md) | [(6.66)](/filings/0000950170-25-065890.md) | [(7.50)](/filings/0001628280-25-038378.md) | not reported | [(0.57)](/filings/0001628280-26-005569.md) | [0.46](/filings/0001628280-26-032139.md) | [(0.06)](/filings/0001628280-26-054339.md) | not reported | [(0.12)](/filings/0001628280-26-005569.md) | [0.04](/filings/0001628280-26-032139.md) | [0.03](/filings/0001628280-26-054339.md) |
| Basic EPS | $ per share | not reported | [0.58](/filings/0000950170-25-015440.md) | [(6.66)](/filings/0000950170-25-065890.md) | [(7.50)](/filings/0001628280-25-038378.md) | not reported | [(0.57)](/filings/0001628280-26-005569.md) | [0.50](/filings/0001628280-26-032139.md) | [(0.06)](/filings/0001628280-26-054339.md) | not reported | [(0.12)](/filings/0001628280-26-005569.md) | [0.04](/filings/0001628280-26-032139.md) | [0.03](/filings/0001628280-26-054339.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Current assets | $m | [226](/filings/0000950170-24-130642.md) | [228](/filings/0000950170-24-012642.md) | [233](/filings/0000950170-24-057667.md) | [240](/filings/0000950170-24-094836.md) | [266](/filings/0001628280-25-053372.md) | [200](/filings/0000950170-25-015440.md) | [232](/filings/0000950170-25-065890.md) | [190](/filings/0001628280-25-038378.md) | [191](/filings/0001628280-26-054339.md) | [186](/filings/0001628280-26-005569.md) | [204](/filings/0001628280-26-032139.md) | [212](/filings/0001628280-26-054339.md) |
| Total assets | $m | [1,298](/filings/0000950170-24-130642.md) | [1,265](/filings/0000950170-24-012642.md) | [987](/filings/0000950170-24-057667.md) | [674](/filings/0000950170-24-094836.md) | [702](/filings/0001628280-25-053372.md) | [618](/filings/0000950170-25-015440.md) | [666](/filings/0000950170-25-065890.md) | [637](/filings/0001628280-25-038378.md) | [631](/filings/0001628280-26-054339.md) | [602](/filings/0001628280-26-005569.md) | [617](/filings/0001628280-26-032139.md) | [621](/filings/0001628280-26-054339.md) |
| Current liabilities | $m | [148](/filings/0000950170-24-130642.md) | [120](/filings/0000950170-24-012642.md) | [107](/filings/0000950170-24-057667.md) | [183](/filings/0000950170-24-094836.md) | [217](/filings/0001628280-25-053372.md) | [152](/filings/0000950170-25-015440.md) | [158](/filings/0000950170-25-065890.md) | [108](/filings/0001628280-25-038378.md) | [101](/filings/0001628280-26-054339.md) | [99.2](/filings/0001628280-26-005569.md) | [107](/filings/0001628280-26-032139.md) | [102](/filings/0001628280-26-054339.md) |
| Total liabilities | $m | [603](/filings/0000950170-24-130642.md) | [534](/filings/0000950170-24-012642.md) | [524](/filings/0000950170-24-057667.md) | [520](/filings/0000950170-24-094836.md) | [561](/filings/0001628280-25-053372.md) | [497](/filings/0000950170-25-015440.md) | [516](/filings/0000950170-25-065890.md) | [481](/filings/0001628280-25-038378.md) | [480](/filings/0001628280-26-054339.md) | [452](/filings/0001628280-26-005569.md) | [458](/filings/0001628280-26-032139.md) | [455](/filings/0001628280-26-054339.md) |
| Long-term debt | $m | [276](/filings/0000950170-24-130642.md) | [277](/filings/0000950170-24-012642.md) | [279](/filings/0000950170-24-057667.md) | [193](/filings/0000950170-24-094836.md) | [195](/filings/0001628280-25-053372.md) | [196](/filings/0000950170-25-015440.md) | [198](/filings/0000950170-25-065890.md) | [199](/filings/0001628280-25-038378.md) | [200](/filings/0001628280-26-054339.md) | [172](/filings/0001628280-26-005569.md) | [173](/filings/0001628280-26-032139.md) | [173](/filings/0001628280-26-054339.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [86.9](/filings/0000950170-24-094836.md) | [87.1](/filings/0001628280-25-053372.md) | [60.0](/filings/0000950170-25-015440.md) | [60.1](/filings/0000950170-25-065890.md) | [0.0](/filings/0001628280-25-038378.md) | [0.0](/filings/0001628280-26-054339.md) | [0.0](/filings/0001628280-26-005569.md) | [0.0](/filings/0001628280-26-032139.md) | [0.0](/filings/0001628280-26-054339.md) |
| Shareholders' equity | $m | [695](/filings/0001628280-25-053372.md) | [731](/filings/0000950170-25-065890.md) | [463](/filings/0001628280-25-038378.md) | [154](/filings/0001628280-25-038378.md) | [141](/filings/0001628280-26-054339.md) | [121](/filings/0001628280-26-032139.md) | [127](/filings/0001628280-26-054339.md) | [156](/filings/0001628280-26-054339.md) | [151](/filings/0001628280-26-054339.md) | [150](/filings/0001628280-26-032139.md) | [159](/filings/0001628280-26-054339.md) | [166](/filings/0001628280-26-054339.md) |

- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.3 d](/filings/0001628280-25-053372.md) | [(2.8)](/filings/0000950170-25-015440.md) | [1.0 d](/filings/0000950170-25-065890.md) | [12.9 d](/filings/0001628280-25-038378.md) | [6.1 d](/filings/0001628280-25-053372.md) | [9.3](/filings/0001628280-26-005569.md) | [15.5 d](/filings/0001628280-26-032139.md) | [23.7 d](/filings/0001628280-26-054339.md) | [12.8 d](/filings/0001628280-25-053372.md) | [37.9](/filings/0001628280-26-005569.md) | [14.1 d](/filings/0001628280-26-032139.md) | [20.0 d](/filings/0001628280-26-054339.md) |
| Capital expenditure | $m | [1.5 d](/filings/0001628280-25-053372.md) | [0.9](/filings/0000950170-25-015440.md) | [1.8 d](/filings/0000950170-25-065890.md) | [0.8 d](/filings/0001628280-25-038378.md) | [1.4 d](/filings/0001628280-25-053372.md) | [1.4](/filings/0001628280-26-005569.md) | [2.3 d](/filings/0001628280-26-032139.md) | [7.7 d](/filings/0001628280-26-054339.md) | [3.0 d](/filings/0001628280-25-053372.md) | [2.2](/filings/0001628280-26-005569.md) | [0.5 d](/filings/0001628280-26-032139.md) | [0.3 d](/filings/0001628280-26-054339.md) |
| Share repurchases | $m | [0.1 d](/filings/0001628280-25-053372.md) | [6.2](/filings/0000950170-25-015440.md) | [3.5 d](/filings/0000950170-25-065890.md) | [0.1 d](/filings/0001628280-25-038378.md) | [0.0 d](/filings/0001628280-25-053372.md) | [1.4](/filings/0001628280-26-005569.md) | [0.8 d](/filings/0001628280-26-032139.md) | [0.0 d](/filings/0001628280-26-054339.md) | [0.2 d](/filings/0001628280-25-053372.md) | [7.5](/filings/0001628280-26-005569.md) | [0.0 d](/filings/0001628280-26-032139.md) | [0.1 d](/filings/0001628280-26-054339.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.0](/filings/0000950170-24-012642.md) | [40.2](/filings/0000950170-24-057667.md) | [40.3](/filings/0000950170-24-094836.md) | [49.3](/filings/0000950170-25-015440.md) | [41.7](/filings/0000950170-25-065890.md) | [41.8](/filings/0001628280-25-038378.md) | [42.9](/filings/0001628280-26-005569.md) | [51.5](/filings/0001628280-26-032139.md) | [43.3](/filings/0001628280-26-054339.md) | [45.0](/filings/0001628280-26-005569.md) | [46.9](/filings/0001628280-26-032139.md) | [47.7](/filings/0001628280-26-054339.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,230,257 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054339.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.